 Connection
Grover Miller to Enzyme Inhibitors
This is a "connection" page, showing publications Grover Miller has written about Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.835 |
|
|
|
-
Davis MA, Barnette DA, Flynn NR, Pidugu AS, Swamidass SJ, Boysen G, Miller GP. CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches. Chem Res Toxicol. 2019 06 17; 32(6):1151-1164.
Score: 0.558
-
Hartman JH, Miller GP, Boysen G. Inhibitory potency of 4-carbon alkanes and alkenes toward CYP2E1 activity. Toxicology. 2014 Apr 06; 318:51-8.
Score: 0.098
-
Hartman JH, Boysen G, Miller GP. CYP2E1 metabolism of styrene involves allostery. Drug Metab Dispos. 2012 Oct; 40(10):1976-83.
Score: 0.088
-
Collom SL, Laddusaw RM, Burch AM, Kuzmic P, Perry MD, Miller GP. CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds. J Biol Chem. 2008 Feb 08; 283(6):3487-3496.
Score: 0.064
-
Bostian AC, Maddukuri L, Reed MR, Savenka T, Hartman JH, Davis L, Pouncey DL, Miller GP, Eoff RL. Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells. Chem Res Toxicol. 2016 Jan 19; 29(1):101-8.
Score: 0.028
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|